Needham Reiterates Buy on Blueprint Medicines, Maintains $133 Price Target
Portfolio Pulse from Benzinga Newsdesk
Needham analyst Ami Fadia has reiterated a Buy rating on Blueprint Medicines (NASDAQ:BPMC) and maintained a price target of $133.
October 30, 2024 | 11:50 am
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
Needham analyst Ami Fadia has reiterated a Buy rating on Blueprint Medicines and maintained a price target of $133, indicating confidence in the company's future performance.
The reiteration of a Buy rating and maintenance of a $133 price target by Needham suggests a positive outlook for Blueprint Medicines. This can lead to increased investor confidence and potential upward movement in the stock price.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100